Candida vaginitis: self-reported incidence and associated costs
- PMID: 10782746
- DOI: 10.1097/00007435-200004000-00009
Candida vaginitis: self-reported incidence and associated costs
Abstract
Background and objectives: Incidence of Candida vaginitis by age and racial or ethnic group is poorly described.
Goal: Estimate incidence, cumulative probability of presumed C vaginitis by age, racial or ethnic group, and associated costs.
Study design: Random digit-dialing survey of 2000 US women.
Results: A total of 6.5 percent (95% CI, 5.4-7.5%) of women older than 18 years reported a least one episode of presumed C vaginitis during the previous 2 months. Women reporting a 1-year period with four or more episodes comprised 8.0% of the sample but accounted for 37.2% of women reporting episodes. Black women reported approximately three times more yeast infections in the previous 2 months (17.4%; 95% CI, 11.2-23.5%) than white women (5.8%; 95% CI, 4.7-6.9%).
Conclusion: The high incidence and the propensity for recurrence underscore the need for a better understanding of the epidemiology and pathogenesis, and stress the need for the development of more accurate, rapid diagnostics and effective treatments.
Similar articles
-
Epidemiology of vaginitis.Am J Obstet Gynecol. 1991 Oct;165(4 Pt 2):1168-76. doi: 10.1016/s0002-9378(12)90722-x. Am J Obstet Gynecol. 1991. PMID: 1951572
-
Prevalence of Candida spp. and age-related disparities amongst women presenting with vaginitis at the Obstetrics and Gynaecology (O&G) Clinic in a Tertiary hospital in Port Harcourt, Nigeria.Afr Health Sci. 2020 Mar;20(1):51-58. doi: 10.4314/ahs.v20i1.9. Afr Health Sci. 2020. PMID: 33402892 Free PMC article.
-
Global burden of recurrent vulvovaginal candidiasis: a systematic review.Lancet Infect Dis. 2018 Nov;18(11):e339-e347. doi: 10.1016/S1473-3099(18)30103-8. Epub 2018 Aug 2. Lancet Infect Dis. 2018. PMID: 30078662
-
Treatment of vaginal Candida infections.Expert Opin Pharmacother. 2002 Aug;3(8):1059-65. doi: 10.1517/14656566.3.8.1059. Expert Opin Pharmacother. 2002. PMID: 12150685 Review.
-
Pathogenesis and epidemiology of vulvovaginal candidiasis.Ann N Y Acad Sci. 1988;544:547-57. doi: 10.1111/j.1749-6632.1988.tb40450.x. Ann N Y Acad Sci. 1988. PMID: 3063184 Review.
Cited by
-
Host-microbe interaction paradigms in acute and recurrent vulvovaginal candidiasis.Cell Host Microbe. 2024 Oct 9;32(10):1654-1667. doi: 10.1016/j.chom.2024.08.018. Cell Host Microbe. 2024. PMID: 39389030 Review.
-
Inflammatory cytokine signalling in vulvovaginal candidiasis: a hot mess driving immunopathology.Oxf Open Immunol. 2024 Aug 17;5(1):iqae010. doi: 10.1093/oxfimm/iqae010. eCollection 2024. Oxf Open Immunol. 2024. PMID: 39234208 Free PMC article. Review.
-
Impaired neutrophil extracellular trap-forming capacity contributes to susceptibility to chronic vaginitis in a mouse model of vulvovaginal candidiasis.Infect Immun. 2024 Mar 12;92(3):e0035023. doi: 10.1128/iai.00350-23. Epub 2024 Jan 30. Infect Immun. 2024. PMID: 38289125 Free PMC article.
-
Race and ethnicity: Risk factors for fungal infections?PLoS Pathog. 2023 Jan 5;19(1):e1011025. doi: 10.1371/journal.ppat.1011025. eCollection 2023 Jan. PLoS Pathog. 2023. PMID: 36602962 Free PMC article. Review.
-
Oral Ibrexafungerp for Vulvovaginal Candidiasis Treatment: An Analysis of VANISH 303 and VANISH 306.J Womens Health (Larchmt). 2023 Feb;32(2):178-186. doi: 10.1089/jwh.2022.0132. Epub 2022 Oct 17. J Womens Health (Larchmt). 2023. PMID: 36255448 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical